BOEHRINGER INGELHEIM’S SURVODUTIDE ACHIEVES UP TO 13.1% WEIGHT LOSS IN NEW PHASE III TRIAL, ALONGSIDE SIGNIFICANT IMPROVEMENTS IN GLYCEMIC CONTROL IN PEOPLE WITH OBESITY AND TYPE 2 DIABETES

Reuters · 1d ago

Please log in to view news